Evidence map›Paper›PMID 40159281›Full record

Observational studyJournal of clinical and experimental hematopathology : JCEH2025

Real-world use of BTK inhibitors for chronic lymphocytic leukemia in Japan: A retrospective observational database study.

Momoko Nishikori, Kenji Nozaki, Yuko Hayashi, Yoshifumi Arita, Masakazu Fujiwara, Chikako Iwao, Hiroshi Kitagawa, Dai Maruyama

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of clinical and experimental hematopathology : JCEH, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Momoko NishikoriDepartment of Hematology, Kyoto University Hospital, Kyoto, Japan.
Kenji NozakiAstraZeneca K.K., Osaka, Japan.
Yuko HayashiAstraZeneca K.K., Osaka, Japan.
Yoshifumi AritaAstraZeneca K.K., Osaka, Japan.
Masakazu FujiwaraAstraZeneca K.K., Osaka, Japan.
Chikako IwaoAstraZeneca K.K., Osaka, Japan.
Hiroshi KitagawaAstraZeneca K.K., Osaka, Japan.
Dai MaruyamaDepartment of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Little is known about real-world treatment practices for chronic lymphocytic leukemia (CLL) in Japan. We aimed to assess the time to discontinuation/dose reduction of Bruton tyrosine kinase inhibitors (BTKis) in patients with CLL in a real-world clinical setting in Japan. This was a retrospective observational database study using data from the Medical Data Vision database (from 1 May 2016 to 30 September 2021). Among the 483 patients with CLL who were treated with BTKis, 182 (37.7%) started treatment with a reduced dose of BTKi (lower than the standard dose), 302 (62.5%) experienced at least one dose reduction during the study period, and 123 (25.5%) discontinued BTKi treatment early (for any reason) during the study period. The median time to BTKi discontinuation was 52.3 weeks in 286 patients who started treatment with a standard dose and 57.1 weeks in 182 patients who started treatment with a reduced dose. The use of prophylaxis with anti-infectives was similar during treatment with BTKis and non-BTKis. There was no major difference in the incidence rate of cardiovascular-related adverse events during treatment with BTKis and non-BTKis. This study provides valuable information for future research on the treatment of CLL patients in Japan.

Indexed as

Agammaglobulinaemia Tyrosine KinaseLeukemia, Lymphocytic, Chronic, B-CellProtein Kinase InhibitorsAdultAgedAged, 80 and overDatabases, FactualFemaleHumansJapanMaleMiddle AgedRetrospective StudiesAgammaglobulinaemia Tyrosine KinaseBTK protein, humanProtein Kinase InhibitorsBruton tyrosine kinase inhibitorschronic lymphocytic leukemiadatabase studyJapan

Identifiers

PMID40159281
PMCPMC12051423

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.